Observation on clinical efficacy of sintilimab in the treatment of advanced non-small-cell lung cancer
Objective To analyze the clinical efficacy of sintilimab in the treatment of advanced non-small-cell lung cancer.Methods 60 patients with advanced non-small-cell lung cancer were selected as research subjects and divided into a control group(30 cases)and an observation group(30 cases)according to random ball-touching method.The control group was treated with paclitaxel and cisplatin combined chemotherapy(TP regimen),and the observation group was treated with sintilimab combined with TP regimen.Patients in both groups were compared in terms of short-term efficacy,occurrence of side effects,detection of T lymphocyte subsets,levels of basic fibroblast growth factor(bFGF)and vascular endothelial growth factor(VEGF),and the quality of life score before and after treatment.Results The objective remission rate and disease control rate of the observation group were 36.67%and 83.33%,which were higher than 10.00%and 40.00%of the control group(P<0.05).After treatment,CD3+,CD4+and CD4+/CD8+in the observation group were higher than those before treatment,while CD8+was lower than that before treatment;the observation group had CD3+of(55.05±6.07)%,CD4+of(37.21±5.80)%and CD4+/CD8+of(2.03±0.39),which were higher than(35.39±5.56)%,(20.16±5.30)%and(0.98±0.47)in the control group;CD8+was(17.60±3.79)%in the observation group,which was lower than(21.72±4.44)%in the control group(P<0.05).In the control group,CD3+,CD4+,CD4+/CD8+decreased after treatment compared with those before treatment(P<0.05),and CD8+was not statistically significant compared with that before treatment(P>0.05).After treatment,the levels of bFGF and VEGF in both groups decreased significantly compared with those before treatment;the observation group had bFGF of(13.03±4.58)ng/L and VEGF of(256.38±76.01)ng/L,which were lower than(19.26±5.06)and(309.71±95.71)ng/L in the control group(P<0.05).The incidence of diarrhea,pneumonia,liver function abnormality,bone marrow suppression,proteinuria,and infusion reaction in the observation group was not statistically significant when compared with that of the control group(P>0.05).After treatment,the scores of energy,general health,somatic pain,physical function,and social function in both groups were significantly higher than those before treatment;in the observation group,the energy score was(62.53±7.06)points,the general health score was(66.84±6.47)points,the somatic pain score was(67.91±7.09)points,the physical function score was(58.50±6.09)points,and the social function score was(73.50±6.47)points,which were higher than(55.96±6.89),(62.91±6.26),(62.12±6.23),(51.40±6.40),and(69.93±4.32)points in the control group(P<0.05).Conclusion Sintilimab has obvious efficacy in the treatment of advanced non-small-cell lung cancer,which can improve the T lymphocyte subset index as well as the levels of bFGF and VEGF,and there is no significant increase in the risk of side effects,and the quality of patients'survival is significantly improved,which has a high clinical application value.
万方数据
维普
